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Surrogate endpoints and event-driven trials in pulmonary arterial hypertension
Although it remains serious and life-threatening, there has been steady progress in pulmonary arterial hypertension (PAH) treatment over the last few decades. 1 Physicians can now target several different pathways with a range of pulmonary vasodilators, either alone or in combination. 2 The bulk of pulmonary vasodilators were approved using 6-min walk distance, a surrogate outcome, as the primary study endpoint. This has led to a robust conversation about the use of surrogates in PAH and their place in clinical trials. In particular, concerns have been raised as to whether haemodynamic surrogates reflect clinically relevant outcomes in PAH. 3, 4 A meta-analysis of PAH trials found that, while change in haemodynamics over 12 weeks was correlated with both treatment and outcomes, only a small fraction of improvement in clinical outcomes could be explained by the change in haemodynamics. 4 If this meta-analysis is true and generalizable, reliance on haemodynamic surrogates could provide misleading impressions when evaluating drug efficacy. Pharmaceutical companies and regulators have subsequently moved away from short-term trials using surrogates and towards longer trials with a focus on clinically relevant endpoints. 5 The best approach to identifying clinically relevant endpoints in PAH trials should be considered a work in progress. Composite outcomes, such as are used in SERAPHIN, have several merits including increased study efficiency, diminished impact of competing risks, and the ability to capture multiple aspects of a treatment effect. 6 On the other hand, powering studies for a composite outcome diminishes the ability to discriminate differences in components of the composite and may create a false sense of equivalency. Important differences in death or hospitalization may be obscured, especially if a component of the composite outcome is driven by a surrogate endpoint with intermediate relevance to clinical progression. 7 Nevertheless, the paradigm shift in PAH trials away from surrogate endpoints and toward clinically relevant outcomes is an important step toward further improving the quality of trials in PAH. The move toward clinically relevant endpoints in trials does not imply that surrogate endpoints are irrelevant in PAH. Proactive clinicians try not to wait for clinically relevant events, such as hospitalization or death, to make changes in therapy. Instead, for better or worse, functional, haemodynamic, or biochemical metrics are used clinically as surrogates to inform prognosis and determine whether treatment is adequate.
The SERAPHIN substudy on invasive haemodynamics
In this issue of the journal, investigators present the results of an invasive haemodynamic substudy from a randomized controlled trial of macitentan in participants with PAH (SERPAHIN). 8 Macitentan was associated with improved mean PA pressure, cardiac index, pulmonary vascular resistance, and N-terminal pro-brain natriuretic peptide (NT-proBNP). The authors characterized improvement in several subgroups including participants with differing functional class and participants who were and were not on background therapy. While no difference was found between the groups, this was intended to explore factors hypothesized to drive treatment heterogeneity. Change in haemodynamic parameters over 6 months was not associated with prognosis in SERAPHIN. This is not surprising. As the authors note, focusing only on change ignores underlying disease severity. It is intuitive that a patient with mild disease and a small improvement in haemodynamics will typically do better than a patient with severe disease who has a moderate improvement in haemodynamics. 9 On the other hand, baseline haemodynamics and haemodynamics at 6 months (which incorporate both baseline disease severity and improvement with treatment) were associated with clinical progression. Had the treatment interval been longer than 6 months, perhaps even the rate of change in haemodynamic parameters alone would have been predictive. The study concludes by showing that favourable haemodynamics and NT-proBNP at 6 months (cardiac index >2.5 L/min/m 2 , right atrial pressure <8 mmHg, and NT-proBNP <median) are associated with reduced risk for morbidity/mortality over subsequent follow-up. The likelihood of achieving these low-risk features was higher with macitentan treatment.
Two core concepts in this study are laudable and speak to the heart of the challenge faced in the clinical care of PAH patients: (i) the attempt to understand treatment heterogeneity; and (ii) the attempt to characterize treatment response and goals.
Understanding treatment heterogeneity
While the authors did not find a differential treatment response by functional class or background therapy, they looked for these differences. Understanding sources of treatment heterogeneity are important given the relevance of differential response to prognostication and potentially to treatment selection. 10 Expensive head-tohead trials are not likely to guide PAH care in the near future and so the PAH community needs to use observational research to understand subpopulations that may be more or less likely to benefit from specific drugs. 10 The authors compared treatment response in pre-specified groups. Alternatively, one could explore a range of participant characteristics for those who did and did not respond to treatment. Inference on such broad exploratory analyses must be cautious given that differences in characteristics may be observed by chance alone. That having been said, characteristics that: (i) differ dramatically in responders; (ii) differ consistently in multiple different studies; or (iii) differ along lines of biological plausibility can still provide insight even with the limitations of observational research.
11,12
Characterizing treatment response and goals
The authors also evaluated prognosis when specific haemodynamic treatment goals were met. Identifying treatment response or nonresponse is a cornerstone of clinical care, and goal-directed therapy is increasingly accepted in PAH. 13 If a poor response is clearly defined using reliable surrogate endpoints, a clinician can more quickly and accurately escalate or replace therapy. In the current trial, morbidity/ mortality were much higher for participants who did not achieve a 'low-risk' pulmonary vascular resistance and NT-proBNP. Future efforts could potentially characterize surrogates of treatment response with even greater precision. It is possible for treatments to be associated with improved haemodynamics, improved haemodynamics to be associated with fewer clinical events, and treatment to be associated with fewer clinical events; however, change in haemodynamics may still explain relatively little of the treatmentrelated improvement in clinical events. 4 Although counterintuitive, this highlights the fact that markers of association alone can be insufficient to conceptualize treatment effect and attributable benefit. If a surrogate accounts for only a small proportion of treatment effect, clinicians may abandon a valuable treatment or add an unnecessary 14 Proposed surrogates should clearly account for a large proportion of the treatment effect before being widely adopted as a treatment goal. Assuming a surrogate does explain a large proportion of the treatment effect, the specific goal threshold could be approached more openly. 15 Goals for surrogates in the current study were adopted from the ESC/ERS 2015 PAH guidelines. 2 Achieving a 'low-risk' profile was clearly associated with improved outcomes; however, it is not known from the manuscript whether thresholds in the 'low-risk' profile were the most appropriate. Was a cardiac index of 2.5 L/min/m 2 the most accurate predictor of morbidity and mortality? Would a different threshold have been more appropriate? Does a threshold even exist or is a higher cardiac index always better than a lower one? The specific threshold at which a surrogate delineates the impression of effective treatment response is important and can dictate whether to add a medication, remove a medication with a borderline response, or continue current management. 16 In conclusion, Galiè et al. do an excellent job of highlighting and addressing challenges faced by PAH clinicians. Namely, the authors prioritize an analysis exploring treatment heterogeneity and address what may constitute an adequate treatment response. Ideally many of these questions would be answered with clinical trials, but-in their absence-high quality observational analyses may be best suited to inform practice. Although there are some limitations to the approach, the cohort of PAH patients assembled by clinical trials may help to answer many questions about treatment heterogeneity and response ( Figure 1) .
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